Shandong Boan Biotechnology Co., Ltd. (HKG:6955)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.77
-0.13 (-2.20%)
Last updated: May 28, 2026, 11:20 AM HKT
Market Cap3.67B -31.5%
Revenue (ttm)873.36M +8.1%
Net Income7.95M -90.2%
EPS0.01 -90.9%
Shares Out 622.33M
PE Ratio461.86
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,060,600
Open5.90
Previous Close5.90
Day's Range5.74 - 5.94
52-Week Range5.73 - 19.90
Beta0.05
Analystsn/a
Price Targetn/a
Earnings DateJun 3, 2026

About HKG:6955

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of post... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 714
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6955
Full Company Profile

Financial Performance

In 2025, HKG:6955's revenue was 784.82 million, an increase of 8.06% compared to the previous year's 726.32 million. Earnings were 7.14 million, a decrease of -90.24%.

Financial numbers in CNY Financial Statements